SLXN Stock Summary and Trading Ideas (Silexion Therapeutics - | NASDAQ:SLXN)

Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.

Silexion Therapeutics - trades on the NASDAQ stock market under the symbol SLXN.

As of January 23, 2026, SLXN stock price climbed to $2.17 with 19,253 million shares trading.

SLXN has a beta of -0.42, meaning it tends to be less sensitive to market movements. SLXN has a correlation of 0.00 to the broad based SPY ETF.

SLXN has a market cap of $6.78 million. This is considered a Sub-Micro Cap stock.

SLXN has underperformed the market in the last year with a return of -78.0%, while the SPY ETF gained +14.2%. In the last 3 month period, SLXN fell short of the market, returning -35.6%, while SPY returned +2.9%. However, in the most recent 2 weeks SLXN has outperformed the stock market by returning +2.4%, while SPY returned -0.7%.

SLXN support price is $1.98 and resistance is $2.33 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SLXN shares will trade within this expected range on the day.